ūüéČ Health Canada Provides a No Objection Letter for ATMA‚Äôs N500 Phase II Clinical Trial Application

ATMA News

ATMA to Provide Psychedelic-Assisted Therapy Training in French and Spanish in the Fall

CALGARY, AB,¬†May 4, 2023¬†/CNW/ –¬†ATMA Journey Centers Inc.¬†(“ATMA”),¬†Canada’s¬†leading psychedelic-assisted therapy training provider, will roll out the first full psychedelic training program in French and Spanish, highly focused on psilocybin and …

ATMA to Provide Psychedelic-Assisted Therapy Training in French and Spanish in the Fall Read More »

ATMA Submits N500 MDMA Phase II Clinical Trial Application to Health Canada

 ATMA Journey Centers Inc. (“ATMA”), Canada’s leading psychedelic-assisted therapy training provider, is pleased to announce it has submitted an N500 3,4-Methylenedioxymethamphetamine (MDMA) phase II Clinical Trial Application (CTA) to Health Canada, which aims …

ATMA Submits N500 MDMA Phase II Clinical Trial Application to Health Canada Read More »

Optimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy Therapists

First-of-its-kind clinical trial establishes the Company‚Äôs drug pipeline and strategic plan to supply thousands of therapists VANCOUVER, British Columbia, Feb. 07, 2023 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) …

Optimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy Therapists Read More »

ATMA OFFERS PSYCHEDELIC-ASSISTED THERAPY TRAINING IN AUSTRALIA TO SUPPORT PSYCHIATRISTS AND HEALTHCARE PROFESSIONALS

In response to¬†Australia’s¬†approval of MDMA and psilocybin use in therapy AUSTRALIA,¬†Feb. 7, 2023¬†/PRNewswire/ —¬†ATMA Journey Centers Inc.¬†(“ATMA”),¬†Canada’s¬†leading psychedelic-assisted therapy training provider, is pleased to offer its psychedelic therapy training programs …

ATMA OFFERS PSYCHEDELIC-ASSISTED THERAPY TRAINING IN AUSTRALIA TO SUPPORT PSYCHIATRISTS AND HEALTHCARE PROFESSIONALS Read More »

ATMA Provides Alberta Health Services (AHS) Healthcare Professionals Group Discount on Psychedelic Therapy Education

CALGARY, ALBERTA, CANADA, January 25, 2023 /EINPresswire.com/ — In response to the new Alberta Regulations on psychedelic assisted therapy,¬†ATMA Journey Centers Inc.¬†(“ATMA”), Canada‚Äôs leading psychedelic-assisted therapy training provider, has announced …

ATMA Provides Alberta Health Services (AHS) Healthcare Professionals Group Discount on Psychedelic Therapy Education Read More »

ATMA and Neuma Centre Partner to Create Access to first of its kind Psilocybin Research Trial in Ontario

KINGSTON, ONTARIO, CANADA, January 5, 2023 /EINPresswire.com/ —¬†ATMA Journey Centers Inc. (“ATMA”), a Canada‚Äôs leading psychedelic-assisted therapy training providers, is pleased to announce their affiliate partnership with¬†Neuma Centre, Kingston‚Äôs first …

ATMA and Neuma Centre Partner to Create Access to first of its kind Psilocybin Research Trial in Ontario Read More »